Skip to main content
. 2023 Oct 6;23:1067. doi: 10.1186/s12913-023-10038-0

Fig. 1.

Fig. 1

Summary of the costs of the current and alternative schemes (a), and the proportion of additional vaccine costs associated with the alternative scheme offset by fewer AE-associated costs and lower programmatic costs (b)

Current scheme (pentavalent; DTwP-Hib-HB plus IPV) and alternative (hexavalent; DTaP-Hib-HB-IPV)